Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/395
A61K-051/00
출원번호
UP-0436347
(1999-11-09)
등록번호
US-7682612
(2010-04-21)
발명자
/ 주소
White, Christine A.
Grillo-López, Antonio J.
Curd, John G.
Desmond-Hellmann, Susan
출원인 / 주소
Biogen Idec Inc.
Genentech, Inc.
대리인 / 주소
Sidley Austin LLP
인용정보
피인용 횟수 :
54인용 특허 :
44
초록
Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.
대표청구항▼
What is claimed is: 1. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled anti-CD20 an
What is claimed is: 1. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody. 2. A method according to claim 1, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg. 3. A method according to claim 1, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg. 4. A method according to claim 1, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg. 5. A method according to claim 1, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m2. 6. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m2, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody. 7. A method according to claim 6, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m2. 8. A method according to claim 1 or 6, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia. 9. A method according to claim 1 or 6, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia. 10. A method according to claim 9, wherein the patient is refractory to fludarabine. 11. A method according to claim 1 or 6, wherein the anti-CD20 antibody is a chimeric antibody. 12. A method according to claim 11, wherein the anti-CD20 antibody is rituximab. 13. A method according to claim 1 or 6, wherein the anti-CD20 antibody is a humanized antibody. 14. A method according to claim 1 or 6, wherein the anti-CD20 antibody is a human antibody. 15. A method according to claim 1 or 6, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody. 16. A method according to claim 1 or 6, wherein the anti-CD20 antibody is administered to the patient repeatedly. 17. A method according to claim 16, wherein the anti-CD20 antibody is administered to the patient weekly. 18. A method according to claim 16, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks. 19. A method according to claim 16, wherein the anti-CD20 antibody is administered to the patient biweekly. 20. A method according to claim 16, wherein the anti-CD20 antibody is administered to the patient monthly. 21. A method according to claim 1 or 6, wherein the anti-CD20 antibody is administered to the patient parenterally. 22. A method according to claim 21, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion. 23. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody therapy is combined with chemotherapy, wherein the method does not include treatment with a radiolabeled anti-CD20 antibody. 24. A method according to claim 23, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.001 to about 30 mg/kg. 25. A method according to claim 23, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.01 to about 25 mg/kg. 26. A method according to claim 23, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 0.1 to about 20 mg/kg. 27. A method according to claim 23, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 375 mg/m2. 28. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 to about 1500 mg/m2, wherein the anti-CD20 antibody therapy is combined with chemotherapy, and wherein the method does not include treatment with a radiolabeled anti-CD20 antibody. 29. A method according to claim 28, wherein the anti-CD20 antibody is administered to the patient at a dosage of about 500 mg/m2. 30. A method according to claim 23 or 28, wherein the patient has relapsed following previous treatment for the chronic lymphocytic leukemia. 31. A method according to claim 23 or 28, wherein the patient is refractory to a treatment previously administered for the chronic lymphocytic leukemia. 32. A method according to claim 31, wherein the patient is refractory to fludarabine. 33. A method according to claim 23 or 28, wherein the anti-CD20 antibody is a chimeric antibody. 34. A method according to claim 33, wherein the anti-CD20 antibody is rituximab. 35. A method according to claim 23 or 28, wherein the anti-CD20 antibody is a humanized antibody. 36. A method according to claim 23 or 28, wherein the anti-CD20 antibody is a human antibody. 37. A method according to claim 23 or 28, wherein the anti-CD20 antibody comprises a CD20-binding fragment of a chimeric, humanized, or human antibody. 38. A method according to claim 23 or 28, wherein the anti-CD20 antibody is administered to the patient repeatedly. 39. A method according to claim 38, wherein the anti-CD20 antibody is administered to the patient weekly. 40. A method according to claim 38, wherein the anti-CD20 antibody is administered to the patient weekly for about 2 to 10 weeks. 41. A method according to claim 38, wherein the anti-CD20 antibody is administered to the patient biweekly. 42. A method according to claim 38, wherein the anti-CD20 antibody is administered to the patient monthly. 43. A method according to claim 23 or 28, wherein the anti-CD20 antibody is administered to the patient parenterally. 44. A method according to claim 43, wherein the anti-CD20 antibody is administered to the patient by intravenous infusion. 45. A method according to claim 23 or 28, wherein the anti-CD20 antibody therapy and the chemotherapy are administered to the patient concurrently. 46. A method according to claim 23 or 28, wherein the chemotherapy comprises chlorambucil. 47. A method according to claim 23 or 28, wherein the chemotherapy comprises cyclophosphamide. 48. A method according to claim 47, wherein the chemotherapy comprises cyclophosphamide, vincristine, and prednisone (COP). 49. A method according to claim 47, wherein the chemotherapy comprises cyclophosphamide, vincristine, prednisone, and doxorubicin (CHOP). 50. A method according to claim 23 or 28, wherein the chemotherapy comprises vincristine. 51. A method according to claim 23 or 28, wherein the chemotherapy comprises prednisone. 52. A method according to claim 23 or 28, wherein the chemotherapy comprises doxorubicin. 53. A method according to claim 23 or 28, wherein the chemotherapy comprises fludarabine. 54. A method according to claim 23 or 28, wherein the chemotherapy comprises methotrexate. 55. A method according to claim 23 or 28, wherein the chemotherapy comprises cisplatin. 56. A method according to claim 23 or 28, wherein the chemotherapy comprises toremifene. 57. A method according to claim 23 or 28, wherein the chemotherapy comprises tamoxifen. 58. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering an anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein the patient is refractory to fludarabine previously administered for the chronic lymphocytic leukemia, and wherein the method does not include treatment with a radiolabeled anti-CD20 antibody. 59. A method according to claim 6, 28, or 58, wherein radiation is not used in conjunction with the anti-CD20 antibody. 60. A method of treating chronic lymphocytic leukemia in a human patient, comprising administering a therapeutic non-radiolabeled anti-CD20 antibody to the patient in an amount effective to treat the chronic lymphocytic leukemia, wherein radiation is not used in conjunction with said anti-CD20 antibody.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (44)
von Borstel Reid W. (Potomac MD) Bamat Michael K. (Potomac MD) Hiltbrand Bradley M. (Columbia MD), Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis.
Senter Peter D. (Seattle WA) Saulnier Mark G. (Middletown CT) Brown Joseph P. (Seattle WA) Kerr David E. (Seattle WA), Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells.
Gansow Otto A. (3003 Van Ness ; NW #W524 Washington DC 20008) Brechbiel Martin W. (2824 Summerfield Rd. Falls Church VA 22042), Backbone polysubstituted chelates for forming a metal chelate-protein conjugate.
Darrell R. Anderson ; Nabil Hanna ; Roland A. Newman ; Mitchell E. Reff ; William H. Rastetter, Chimeric and radiolabelled antibodies specific to human CD20 antigen and use thereof for treatment of B-cell lymphoma.
Robinson Randy R. (Los Angeles CA) Liu Alvin Y. (Santa Monica CA) Ledbetter Jeffrey A. (Seattle WA), Chimeric antibody with specificity to human B cell surface antigen.
Robinson Randy R. (Walnut Creek CA) Liu Alvin Y. (Seattle WA) Ledbetter Jeffrey A. (Seattle WA), Chimeric antibody with specificity to human B cell surface antigen.
Uhr Jonathan W. (Dallas TX) Vitetta Ellen S. (Dallas TX) Scheuermann Richard H. (Carrollton TX), Epitope-specific monoclonal antibodies and immunotoxins and uses thereof.
Cheever Martin A. ; Disis Mary L., Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is a.
Reff Mitchell E. (San Diego CA), Impaired dominant selectable marker sequence and intronic insertion strategies for enhancement of expression of gene pro.
Abrams, Paul G.; Schroff, Robert W.; Morgan, Jr., Alton C., Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof.
Hudziak Robert M. (Corvallis OR) Shepard H. Michael (Rancho Santa Fe CA) Ullrich Axel (Portola Valley CA) Fendly Brian M. (Half Moon Bay CA), Monoclonal antibodies directed to the HER2 receptor.
Boss Michael A. (Slough GBX) Kenten John H. (High Wycombe GBX) Emtage John S. (High Wycombe GBX) Wood Clive R. (Near Fordingbridge GBX), Multichain polypeptides or proteins and processes for their production.
Kaminski Mark S. (Ann Arbor MI) Butchko Gregory M. (Miami Lakes FL) Glenn Stephan D. (Davie FL) Wahl Richard L. (Ann Arbor MI), Radioimmunotherapy of lymphoma using anti-CD20.
Cabilly Shmuel (Monrovia CA) Heyneker Herbert L. (Burlingame CA) Holmes William E. (Pacifica CA) Riggs Arthur D. (La Verne CA) Wetzel Ronald B. (San Francisco CA), Recombinant immunoglobin preparations.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Anderson Darrell R. ; Hanna Nabil ; Leonard John E. ; Newman Roland A. ; Reff Mitchell E. ; Rastetter William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen.
Anderson, Darrell R.; Hanna, Nabil; Leonard, John E.; Newman, Roland A.; Reff, Mitchell E.; Rastetter, William H., Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, In vivo production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of biologics and proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of oncology-related proteins and peptides.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; Ellsworth, Jeff Lynn; Ejebe, Kenechi; Guild, Justin; John, Matthias; Hatala, Paul; Roy, Atanu; Schrum, Jason P.; Whoriskey, Susan; Wood, Kristy M., Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of proteins associated with human disease.
Bancel, Stephane; Chakraborty, Tirtha; de Fougerolles, Antonin; Elbashir, Sayda M.; John, Matthias; Roy, Atanu; Whoriskey, Susan; Wood, Kristy M.; Hatala, Paul; Schrum, Jason P.; Ejebe, Kenechi; Ellsworth, Jeff Lynn; Guild, Justin, Modified polynucleotides for the production of secreted proteins.
White, Christine A.; Grillo-Lopez, Antonio J.; Curd, John G.; Desmond-Hellmann, Susan, Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.